We are excited to announce that Kevin Finney, our President and CEO, will be participating in the upcoming Stifel, Jefferies London, and Evercore ISI healthcare conferences. ? For more details: https://lnkd.in/gyr2n72g
Autobahn Therapeutics, Inc.
生物技术研究
San Diego，CA 4,212 位关注者
Restoring hope for people affected by CNS disorders
关于我们
Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve. CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people. We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry platform to develop novel, small molecule therapies that harness the regenerative power of the human body, with an initial focus on high unmet need areas neuropsychiatry, neurodegeneration, and neuroinflammation. Our pipeline is led by ABX-002, a centrally-penetrant thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Want to join our team? Please see our open positions on the Careers page of the Autobahn website: https://autobahntx.com/careers/
- 网站
-
https://autobahntx.com
Autobahn Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，CA
- 类型
- 私人持股
- 创立
- 2017
地点
-
主要
获取路线
9880 Campus Point Drive
Suite 440
US，CA，San Diego，92121
Autobahn Therapeutics, Inc.员工
动态
-
Our growing team on another adventure: Kayaking in La Jolla Cove! #autobahnlife #getoutside
-
-
We're pleased to share that the FDA has cleared our IND application for ABX-002 as an adjunctive treatment for bipolar depression.? ? This is a meaningful step in our efforts to advance innovative therapies for #CNSdisorders and expands our #depression program with ABX-002, which is currently being evaluated in the AMPLIFY Phase 2 trial for #majordepressivedisorder. We plan to initiate a Phase 2 trial of ABX-002 in bipolar depression by the end of 2024. ? For more details: https://lnkd.in/g3jfZp-u ? #BipolarDepression #MentalHealth #Biotech
Autobahn Therapeutics Announces FDA Clearance of IND Application for ABX-002 as an Adjunctive Treatment for Bipolar Depression - Autobahn Therapeutics
autobahntx.com
-
As we observe World Mental Health Day, Autobahn is committed to raising awareness around this year’s theme: Mental Health at Work. We understand that a supportive workplace is key to overall well-being, especially for those affected by #CNS disorders such as #majordepressivedisorder and #bipolardisorder – two areas we’ve prioritized in our R&D efforts. ? Our mission extends beyond advancing our research pipeline; we’re focused on creating a work environment that prioritizes mental health for employees, caregivers, and their families. By fostering a culture of understanding and support, we aim to make a meaningful impact in the workplace and in the broader community. ? Let’s work together toward a future where mental health is a top priority at work and in life. ? #WorldMentalHealthDay #MentalHealthAtWork #MentalHealth
On #WorldMentalHealthDay, we reflect on the profound impact #depression has on the workforce. At Autobahn, we are committed to advancing new treatments for depression while advocating for stronger mental health support in the workplace. Read more in my latest article.
World Mental Health Day: How Innovation and Awareness Can Combat Depression in the Workplace
Kevin Finney，发布于领英
-
We have begun our Phase 2 trial of ABX-002 in adults with #majordepressivedisorder. Our therapy is a highly potent, oral drug designed to enhance the CNS benefits of thyroid hormone biology and drug concentrations directly in the brain, for greater potency, efficacy and safety. We will be testing ABX-002 in 230 adults and expect to report topline data in the second half of 2025. With millions of people suffering from depression, new treatments are needed, and we hope ours will help to alleviate the debilitating symptoms that so many face. Read more in our press release: https://lnkd.in/gX3Zy9fB ? #MDD #ClinicalTrials #DrugDevelopment #Biotech #Depression
-
-
We are pleased to share that Kevin Finney, our President and CEO, will be participating in two upcoming investor conferences in September: the 2024 Cantor Global Healthcare Conference and the 2024 BofA Healthcare Trailblazers Private Company Conference. ? For more details: https://lnkd.in/gKu9yvyn
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences - Autobahn Therapeutics
autobahntx.com
-
Autobahn is hiring a VP/SVP of Clinical Opertions. Join our fantastic team! https://lnkd.in/gUx_9Zgw?
-
We have a pipeline of transformative small molecule therapies to treat multiple #CNS disorders, including #majordepressivedisorder and #bipolardisorder depression. With our recent Series C financing, we are advancing these treatments in the clinic to help patients suffering with these conditions. Read more about our progress here: https://lnkd.in/gnzrDDn2
-